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Abstract Post-infectious sequelea such as Guillain Barré
syndrome (GBS), reactive arthritis (RA), and inflammatory
bowel disease (IBD) may arise as a consequence of acute
Campylobacter-enteritis (AE). However, reliable seropreva-
lence data ofCampylobacter-associated sequelae has not been
established. The objectives of this study were, first, to identify
the most specific and sensitive test antigen in an optimized
ELISA assay for diagnosing a previous Campylobacter-infec-
tion and, second, to compare the prevalence of anti-
Campylobacter antibodies in cohorts of healthy blood donors
(BD), AE, GBS, RA, and IBD patients with antibodies against
known GBS, RA and IBD triggering pathogens. Optimized
ELISAs of single and combined Campylobacter-proteins
OMP18 and P39 as antigens were prepared and sera from
AE, GBS, RA and IBD patients and BD were tested for
Campylobcter-specific IgA and IgG antibodies. The results
were compared wi th MIKROGEN™ - recomLine
Campylobacter IgA/IgG and whole cell lysate-immunoblot.
Antibodies specific for Helicobacter pylori, Mycoplasma
pneumoniae, Yersinia enterocolitica, and Borrelia afzeliiwere
tested with commercial immunoblots. ROC plot analysis re-
vealed AUC maxima in the combination of OMP18 and P39
for IgA and in the P39-antigen for IgG. As a result, 34–49 %
GBS cases, 44–62 % RA cases and 23–40 % IBD cases were
associated with Campylobacter-infection. These data show
that Campylobcater-seropositivity in these patient groups is
significantly higher than other triggering pathogens suggest-
ing that it plays an important role in development of GBS and
RA, and supports the hypothesis that recurrent acute
campylobacteriosis triggers IBD.
Introduction
Members of genus Campylobacter are Gram-negative and
microaerophilic bacteria that invade the gastrointestinal tract
of humans causing campylobacteriosis whose clinical symp-
toms include bloody or watery diarrhea, abdominal pain,
fever, headache, nausea and vomiting. Although this acute
enteritis is self-limiting, post-infectious sequelae GBS, RA
and IBD can arise after recovery [1–3]. Recently, C. jejuni
has been found to be the leading cause of bacterial gastroen-
teritis worldwide [4, 5], which has led to renewed interest in
quantifying the seroprevalence of Campylobacter-specific an-
tibodies in the rising cases of GBS, RA and IBD as post-
infectious sequelae.
Recent studies have shown GBS an autoimmune disorder
in which the body’s immune system attacks GM-gangliosides
in the central nervous system leading to acute neuromuscular
paralysis and consecutive muscle weakness succeeding
campylobacteriosis [6]. Furthermore, cytomegaloviruses
(CMV), Epstein-Barr viruses (EBV) and Mycoplasma
pneumonia have been shown to trigger GBS [6]. Presently,
four common types of GBS are recognized vis-á-vis the Miller
Fisher syndrome (MFS), the acute motor axonal neuropathy
(AMAN), the acute inflammatory demyelinating
polyradiculoneuropathy (AIDP) and the acute motor-sensory
axonal neuropa thy (AMSAN) [6] . Impor tan t ly,
A. E. Zautner :C. Johann :A. M. Tareen :W. O. Masanta :
R. Lugert : R. Schmidt-Ott :U. Groß
Institut für Medizinische Mikrobiologie, Universitätsmedizin
Göttingen, Kreuzbergring 57, 37075 Göttingen, Germany
A. E. Zautner (*) :W. O. Masanta
UMG-Labor, Institut für Klinische Chemie/Zentrallabor,
Universitätsmedizin Göttingen, Göttingen, Germany
e-mail: azautne@gwdg.de
A. Strubel :C. Busse




Eur J Clin Microbiol Infect Dis (2014) 33:1019–1027
DOI 10.1007/s10096-013-2040-4
Campylobacter has been linked to trigger MFS, AMAN, and
AMSAN [6].
Similarly, RA has been shown to develop after
campylobacteriosis [7–9]. Like in GBS, other pathogens in-
cluding Salmonella enterica, Shigella dysenteriae, Yersinia
enterocolitica, Yersinia pseudotuberculosis, and Chlamydia
trachomatis have been implicated in triggering RA [7]. In
previous s tudies the inc idence of RA in acute
campylobacteriosis patients was found to range from 1 to
7 % [7, 10]. However, seroprevalence data in RA patients,
with an acute flare up of arthritis has not been estimated so far.
Equivalently, epidemiologic, ecologic and genetic studies
have associated the pathogenesis of IBD, a strictly gastroin-
testinal tract immunological disorder, with interplay between
C. jejuni, host genetic susceptibility, recurrent AE, and com-
mensal microflora [11–15]. It has been revealed that host
genetics influences the diversity and load of commensal mi-
croflora. However, slight alteration in diversity and loads of
members of the commensal microflora of phyla Firmicutes
and Bacterioidetes due to diet and other unknown agents,
promotes intestinal epithelial invasion by C. jejuni leading to
development of IBD [15–17].
The Campylobacter literature shows inconsistence in the
frequency of previous Campylobacter infections in these se-
quelae. As a consequence, there is under- or over-estimation
of Campylobacter-triggered post infectious sequelae. This has
been attributed to lack of reliable serological assays for de-
tecting previous Campylobacter infections due to poor stan-
dardization and cross-reactivity to other pathogens including
Helicobacter spp., Arcobacter spp., Salmonella spp.,
Legionella spp., Yersinia spp., and Corynebacterium spp.
[18–20].
Recently, we reported on a Campylobacter ELISA with
91.9 % sensitivity and 99.0 % specificity that is reliable for
detecting previous Campylobacter antibodies in healthy indi-
viduals (BD), AE-patients and GBS-patients [21]. This assay
is based on a combination of two purified Campylobacter
antigens, namely, OMP18 and P39 [22]. However, the most
specific and sensitive antigen or antigen combination for the
detection of previous Campylobacter infection in a particular
post-infectious sequel remains unknown. Furthermore, the
ability of antigens OMP18 and P39 to diagnose previous
Campylobacter infection in RA-patients and IBD-patients is
also unknown. Clearly, knowledge of the specificity and sen-
sitivity of antigens OMP18 and P39 is important for continu-
ous development of reliable assays for detecting previous
Campylobacter infections in a particular post-infectious
sequel.
In the present study, we investigated the most specific and
sensitive antigen between OMP18, P39 and combined
OMP18+P39 for detectingCampylobacter specific antibodies
in AE-patients and patients of each named post-infectious
sequel; we tested sensitivity and specificity of optimized
OMP18 and P39 ELISA in detecting prior Campylobacter
infections by comparing it’s results with those of antigens
MOMP, PEB1, PEB2, PEB4, OMP18, and P39 embedded
in MIKROGENTM-recomLine Campylobacter IgA/IgG blot
and of a whole cell lysate immunoblot [23]; we used the
optimized OMP18+P39 and P39 ELISA to determine the
seroprevalance of Campylobacter specific IgA and IgG anti-
bodies in BD, AE, GBS, RA, and IBD respectively; we tested
BD, AE, GBS, RA, and IBD sera for the presence of antibod-
ies against Helicobacter pylori and Yersinia enterocolitica
which are known to cross-react with Campylobacter antigens
[24] and Mycoplasma pneumonia and Borrelia afzelii that
cause similar clinical symptoms as those observed in
campylobacteriosis associated post-infectious sequelae.
Materials and methods
Sera tested in the study
Sera tested in this study were collected from 91 GBS patients,
60 AE patients, 50 RA patients, 39 IBD patients and 80 BD.
The GBS cohort comprised of three sera from confirmed
MFS patients and the remaining 88 were AMAN, AIDP and
AMSAN suspected cases, which had not been clinically dis-
tinguished. Mean age of the patients was 61.2±17.1 years; the
age median was 66.0±13.6 years and the proportion of male
to female patients was 46.8 %:53.2 %. The sera of patients
with acute diarrhea and a Campylobacter-positive stool cul-
ture were included as positive control. The mean age of AE
patients was 47.5±24.3 years, the age median was 51.0±
21.1 years, and the proportion of male to female patients
was 59.3 %:40.7 %. The mean age of RA patients was
39.7±22.0 years, the age median was 43.5±19.5 years and
the proportion of male to female patients was 48.0 %:52.0 %.
The serum samples were collected at an acute flare-up stage of
arthritis. The IBD patient group’s age mean was 37.3±
21.5 years, the age median was 38±18.2 years, and the pro-
portion of male to female patients was 40.7 %:59.3 %. The
mean age of BDs was 39.2±21.3 years, the age median was
42.2±20.1 years, and the proportion of male to female patients
was 48.4 %:52.6 %. BD sera were taken in July 2011 to serve
as control group to estimate the seroprevalence of
Campylobacter-specific antibodies in healthy individuals.
All patients had been hospitalized in the University Medical
Center Göttingen from 2001 to 2011 but there were no GBS
cases in 2004 and 2005. All sera were stored at −80 °C until
testing.
Optimized ELISA assays
ELISA embedded with C. jejuni proteins P39 and OMP18 as
antigens, singularly and combined, were prepared. Initially,
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the recombinant proteins P39 and OMP18 were expressed and
purified as described before [22]. Then both proteins were
diluted in bicarbonate buffer (pH=8.4) to a final concentration
of 3.0 μg/mL of P39 and 5.0 μg/mL of OMP18.
NuncMaxiSorp® 96-well plates (Thermo Fisher Scientific Inc.,
Langenselbold, Germany) were coated with 100 μL protein
solution of P39 or OMP18 or P39+OMP18 at room temperature
overnight in a wet chamber. After the coating procedure, the
plates were washed three times with phosphate-buffered saline
(PBS). Thereafter the plates were blocked with 1.0 % BSA in
PBS for one hour at room temperature followed by lyophiliza-
tion. After lyophilization the plates were stored dry. The mea-
surement procedure was performed as described before [22], but
with some modifications. First, the patient sera were used at
1:100 dilutions. The secondary horseradish peroxidase-labeled
goat anti-human IgA and IgG antibodies were used at a dilution
of 1:4000 (anti-human IgA) and 1:50,000 (anti-human IgG;
KPL, Gaithersburg, USA). Therewith, we significantly in-
creased the amount of antigen used and decreased the concen-
tration of the secondary antibody in order to achieve higher
sensitivity than previously described [22]. Signal intensities
above the cut-off value 10.0+1.0 Virotec units (VU=10*OD-
sample/OD-Cut-Off) were considered as positive, below the cut-
off value 10.0 – 1.0 VU were considered as negative, and in the
range of cut-off value 10.0 +/− 1.0 VU were considered as
borderline.
MIKROGEN-recomLine Campylobacter blot and whole cell
lysate-immunoblot
AE andGBS patient and BD sera were tested onMIKROGEN-
recomLine Campylobacter IgA/IgG blot and whole cell lysate-
immunoblot. Analysis using the well-established
recomLineCampylobacter IgA and IgG blot (MIKROGEN
Diagnostik, Neuried, Germany) was done as recommended
by the manufacturer. On the other hand, the whole cell-lysate
(WCL) line-blot was prepared and measurement carried out as
previously described [23]. The evaluation of the sera on the
whole cell lysate-immunoblot was determined by their re-
sponses to PEB1, PEB2, PEB3 and PEB4 antigens [23].
Helicobacter, Mycoplasma, Yersinia, and Borrelia
immunoblots
Helicobacter pylori LINE, Mycoplasma pneumonia LINE,
Yersinia enterocolitica LINE, and Borrelia LINE
Immunoblot assays (Sekisui Virotech GmbH, Rüsselsheim,
Germany) were used for the detection of antibodies against
Helicobacter pylori, Mycoplasma pneumoniae, Yersinia
enterocolitica, and Borrelia afzelii, respectively. The preva-
lence of IgG and IgA antibodies against these pathogens was
determined in all sera except against B. afzeliiwhere only the
prevalence of IgG was determined.
Statistical analyses
The χ2-test was used to test for significant differences. The
obtained p-values are indicated as ‘*’ (p>0.05), ‘**’ (p<0.05),
or ‘***’ (p<0.001) as shown in Table 2. Calculation of ROC
curves and their comparison was performed using the ROC-
Excel-Tool (ACOMED Statistik, Leipzig, Germany).
Results
Determination of OMP18, P39 and OMP18+P39 ROC AUC
values during detection of Campylobacter specific antibodies
in BD, AE, GBS, RA and IBD
Evaluation of OMP18, P39, and OMP18+P39 AUCs re-
vealed that ELISA embedded with antigen combination
OMP18+P39 has a significant advantage in Campylobacter-
specific IgA detection as compared to ELISA embedded with
OMP18 in AE sera (p<0.05; Fig. 1a), in GBS sera (p<0.05;
Fig. 1b) and to ELISA embedded with antigen P39 tested with
GBS sera (p<0.05; Fig. 1c). The comparison of AUCs for the
detection of Campylobacter-specific IgG antibodies showed
no significant differences between ELISAs embedded with
OMP18, P39, and OMP18+P39 except AUC of ELISA em-
bedded with P39 which was significantly larger as compared
to AUC of ELISA embedded with OMP18+P39 (p<0.05;
Fig. 1d) testing GBS sera. ROC AUCs of antigens MOMP,
PEB1, PEB2, and PEB4 and WCL were significantly smaller
compared to antigens OMP18, P39 and OMP18+P39 for both
IgA and IgG (results not shown).
Table 1 lists sensitivity, specificity, positive predictive
values (PPV) and negative predictive values (NPV) of tested
individual antigens OMP18, P39, MOMP, PEB1, PEB2, and
PEB4 as well as the combined antigens OMP18+P39, and
whole cell lysate estimated on sera of stool culture positive
campylobacteriosis patients and healthy blood donors. With a
specificity of approximately 90 % the OMP18, P39 and
OMP18+P39-based ELISAs showed a sensitivity of 57.1 %,
40.7 %, and 38.9 %, respectively, when tested for IgA and
51.9%, 57.4%, and 47.3%, respectively, when tested for IgG.
OMP18 and P39 tested on MIKROGEN recomLine blot
demonstrated≈10 % increase in specificity and≈15 % de-
crease in sensitivity. In contrast, antigens MOMP, PEB1,
PEB2, and PEB4 tested on MIKROGEN recomLine blot
showed 0.0–18.3 % sensitivity when specificity of nearly
100 % was achieved. The selection of the cut-off is based on
optical density raw data in a non-prametric approach. As
shown by the calculated MIKROGEN evaluation index
(Table 1), MOMP, PEB1, PEB2, and PEB4 resulted in 8 %
increase in the specificity of IgA detection as compared to
OMP18+P39 ELISA. The sensitivity and specificity of IgG
antibody detection was reduced by 7 % as compared to that of
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P39 ELISA. The WCL-based blot showed a sensitivity of
28.6 % and a specificity of 96.2 % in the detection of IgA
antibodies and a sensitivity of 48.6 % and a specificity of
83.8 % in the detection of IgG antibodies.
These results show that a line blot or an ELISA based on
antigen P39 and OMP18 have the highest sensitivity and
specificity. Also, incorporation of antigens PEB1, PEB2,
PEB4, and MOMP into line blot does not significantly im-
prove sensitivity or specificity (Table 1).
Evaluation of IgA, IgG and IgA/IgG reactivity in BD, AE,
GBS, RA and IBD sera
OMP18+P39-based ELISA for detection of antibody IgA and
P39-based ELISA for detection of antibody IgG were used to
determine the Campylobacter seroprevalence in BD, AE,
GBS, RA and IBD sera.
As shown in Table 2, the reactivity of IgA antibodies in BD
sera was 9–12 %, in culture-positive AE sera 35–45 %
(p<0.001), in GBS sera 48–55 % (p<0.001), in RA sera 34–
40 % (p<0.05) and in IBD sera it was 26–31 % (p<0.05).
Campylobacter-specific IgA antibody prevalence was high in
GBS followed by AE, RA and IBD sera in that order.
As shown in the same table, the P39-based prevalence of
Campylobacter-specific IgG antibodies in BD was 9–17 %, in
AE it was 52–62 %, in GBS 37–53 %, in RA 54–66 %, and in
IBD it was 44–47 % (p<0.001). Campylobacter-specific IgG
antibody prevalence was high in RA sera followed by AE,
IBD and GBS sera in that order.
Combined IgA/IgG reactivity was found to be 16–26 % in
BD, 62–72 % in AE, 60–65 % in GBS, 70–78 % in RA and
49–56 % in IBD sera.
Comparison of H. pylori, M. pneumoniae, Y. enterocolitica,
and B. afzelii specific antibody prevalences in AE, GBS, RA,
IBD and BD sera
There was no significant difference in H. pylori-specific
antibody-prevalence in AE, RA, and IBD patient sera com-
pared to BD sera. However, antibody-prevalence ofH. pylori-
specific IgA in GBS sera was significantly higher (Table 2);
9–17 % anti-Campylobacter and anti-Helicobacter antibody
Fig. 1 Receiver operating
characteristic (ROC) curves
comparing the antigens/antigen-
combinations P18, P39, and
P39+P18 for the detection of
anti-Campylobacter antibodies.
a Sera of culture-positive acute
Campylobacter-enteritis patients
tested for anti-Campylobacter
IgA. b, c Sera of GBS patients
tested for anti-Campylobacter
IgA. dGBS patients tested for
anti-Campylobacter IgG. AUC
area under the curve, SE standard
error, 0.95 low./upp. CL 0.95
lower and upper confidence
limits, p p-value
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double positive sera were found in all sera (AE, GBS, RA,
IBD, and BD sera). See Table 3 for a particular group.
There was no significant difference in reactivity of anti-
M. pneumonia IgA-antibodies in all sera. But there was a
significant increase (p< 0.05) in the reactivity of
M. pneumonia-specific IgG in AE, RA, and IBD sera but not
in GBS sera (Table 2); 16–23% of all tested sera were positive
for both anti-Campylobacter antibodies and anti-
M. pneumonia antibodies (Table 3); 4 % of GBS sera that
were negative for anti-Campylobacter-reactive antibodies
showed both IgA and IgG antibodies reactive against
M. pneumonia. The anti-Campylobacter antibody and anti-
M. pneumonia antibody double-positive (IgA and IgG) rate
was 23–33 % in GBS sera (results not shown).
The prevalence of Y. enterocolitica-reactive IgA antibodies
significantly increased (p<0.05) in GBS, RA, AE, and IBD
sera. Y. enterocolitica-reactive IgG antibodies significantly
increased (p<0.001) in only RA sera. Also, 15–18 % (IgA),
8–11 % (IgG), and 23–35% (IgA+IgG) of all tested sera were
positive for both Y. enterocolitica- and Campylobacter-reac-
tive antibodies (Table 3). Specifically, a significant increase of
double-positive rate for IgA antibodies was 17–30 % in AE,
19–26% in GBS and 18–26% in RA sera. Increase of double-
positive rate for IgG was 14–16 % in RA sera only. Anti-
Yersinia antibodies (IgA/IgG) in Campylobacter antibody-
negative sera were found in 3–18 %/3–5 % of AE, 12–
19 %/7–9 % of GBS, 10–12 %/6–14 % of RA, and 5–10 %/
8–13 % of IBD sera.
No significant difference in anti-B. afzelii-IgG antibody
prevalence was observed between RA and BD sera.
However, there was a significant increase (p<0.05) in the
prevalence of anti-B. afzelii-IgG antibodies in AE, GBS, and
IBD patients; 13–22 % of all tested sera were anti-
Campylobacter IgA and IgG antibody and anti-Borrelia IgG
antibody double positive (Table 3). This double-positive rate
was significantly (p<0.05) above average in GBS patients
(26–30 %) but below average in RA-patients (6 %) (results
not shown).
Discussion
In a generation of seroprevalence data, antigen or antigen
combination is decisive for the test concerned. Generally, the
reactivity of the immunoglobulin classes IgA and IgG is
determined in Campylobacter serodiagnostics because they
have been found to have high sensi t ivi ty [25] .
Immunoglobulin class IgM is rarely used because of its low
sensitivity [23, 25]. Routine serodiagnostics of prior C. jejuni-
infections is performed using an ELISA or an immunoblot
with whole cell lysate or recombinant antigens [20, 23, 25].
Recombinant antigens including MOMP [26, 27], OMP18
[28], P39 [22], Cj0069 [20], and PEB 1, PEB 2, PEB 3, and
PEB 4 [29] are used to detect Campylobacter specific anti-
bodies. However, the sensitivity of OMP18 and P39 in rela-
tion to MOMP, PEB1, PEB2, PEB3 and PEB4 is unknown.
Therefore, one of the objectives of this study was to deter-
mine which antigen between OMP18, P39 and antigen com-
bination (OMP18+P39) is the most sensitive and specific for
detecting anti-Campylobacter antibodies in the diagnosis of
acute campylobacteriosis and post-infectious sequelae.
According to our data, an ELISA based on the combination
of OMP18+P39 shows the ROC AUC maximum for IgA
antibodies whereas an ELISA based on P39 alone exhibits
the maximal ROCAUC for IgG antibodies. Antigens P39 and
OMP18 as part of the MIKROGEN recomLine blot show
almost the same values for sensitivity, specificity, PPV and
NPV as those of antigens P39 and OMP18 being part of an
ELISA. Therefore, it is evident that a line blot or an ELISA
based only on antigens P39 and OMP18+P39 are the most
sensitive and specific in detecting Campylobacter-specific
antibodies in all patient groups. Additional detection of anti-
MOMP, -PEB1, -PEB2, and -PEB4 immune reactivity does
not significantly improve Campylobacter serology.
Consequently, the testing of antibodies using these antigens
in Campylobacter serology should be discouraged and testing
of antibodies using P39 and OMP18+P39 encouraged.
In this study 16–26 % of healthy BD tested positive for
both Campylobacter-specific IgA and IgG antibodies. The
serum samples of the healthy blood donors were collected
during a summer month in which the Campylobacter
Table 1 Sensitivity, specificity, positive (PPV) and negative predictive
values (NPV) estimated on sera of stool culture positive





PPV [%] NPV [%|
IgA IgG IgA IgG IgA IgG IgA IgG
OMP18 ELISA 57.1 51.9 90.5 90.8 82.1 79.4 73.6 73.4
P39 ELISA 40.7 57.4 90.9 90.5 75.9 81.6 68.6 74.4
OMP18+P39 ELISA 38.9 47.3 91.0 90.8 75.0 78.8 68.3 70.4
MOMP MG 18.3 3.3 100 96.3 100 40.0 62.0 57.0
PEB4 MG 16.7 3.3 100 98.8 100 66.7 61.5 57.7
PEB2 MG 3.3 1.7 100 100 100 100 57.9 57.6
PEB1 MG 0.0 1.7 100 97.5 - 33.3 57.1 56.9
OMP18 MG 41.7 36.7 100 98.8 100 95.7 69.6 67.5
P39 MG 41.7 45.0 98.8 86.3 96.2 71.0 69.3 67.6
Index MG 56.7 50.0 98.8 83.8 97.1 69.8 75.2 69.1
WCL 28.6 48.6 96.2 83.8 76.9 58.6 75.0 77.2
OMP18 outer membrane protein 18 kDa, P39 protein 39 kDa, MOMP
major outer membrane protein, PEB1-4perplasmic-binding proteins 1–4,
Index MG numerical index for test evaluation that is the sum of the
ascribed points of all positive antigens, i.e. bands with coloration more
intense than the cut-off band, WCLwhole cell lysate
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prevalence is higher than in the winter months [30]. This
might expla in the increased prevalence ra te of
Campylobacter-specific antibodies in the healthy blood donor
cohort in comparison to our previous studies [21, 22].
Similarly, 60–65 % of GBS patients tested positive for both
Campylobacter-specific IgA and IgG antibodies; it therefore
follows that 34–49 % (≈42 %) of GBS cases in this study are
statistically associated with campylobacteriosis. Several stud-
ies have investigated the proportion of Campylobacter-trig-
gered GBS and given an impression of an increase in
Campylobacter associated GBS over time. For example,
Winer et al. attributed 14 % [31], Rees et al. attributed 26 %
[32], Jacobs et al. attributed 32 % [33], Hao et al. attributed
45 % [34] and our group attributed 80 % [21] of GBS cases to
Campylobacter. This increase in the detection of seropreva-
lence can been attributed to improved detection methods. In
this study, our data on German patients supports the findings
of Hao et al. who associated 45 % of GBS cases with a prior
Campylobacter infection in a study on a Japanese population
[34] but varies from other studies which underestimated
[31–33] or overestimated [21] the proportion of post-
Campylobacter GBS. However, the varying proportion of
AMAN, AMSAN and MFS cases that have been demonstrat-
ed to be associated with a prior Campylobacter infection
relative to AIDP cases in GBS study populations [6] could
be another reason for these differences in the prevalence of
Campylobacter-specific antibodies. Future studies are re-
quired to address this thought.
Furthermore, we tested all GBS sera for H. pylori-,
M. pneumoniae-, Y. enterocolitica, and B. afzelii-reactive anti-
bodies. The relatively high rate of double Mycoplasma- and
Campylobacter-positive sera of GBS patients (23–33 %) in-
dicates that there could be additive effects triggering autoan-
tibodies causing GBS by sequential (or simultaneous) infec-
tions with M. pneumoniae and C. jejuni. Otherwise, there
could be significant test cross-reactivity between both
bacterial species. The rate of 4 % of Mycoplasma-antibody
positivity in Campylobacter-negative GBS-patients substanti-
ates our data for Campylobacter seroprevalence in GBS pa-
tients, because it delivers valid data explaining the etiology of
the remaining Campylobacter-negative GBS cases.
In contrast to that, the increased rate of double Borrelia and
Campylobacter seropositive GBS patients (26–30 %) indi-
cates an association between Campylobacter-triggered neuro-
nal disease and neuroborreliosis either in antigenic interfer-
ence (serodiagnostics) or even in etiology.
In the present study, we demonstrate a Campylobacter
seroprevalence (IgA+IgG) rate of 70–78 % in RA patients.
By subtracting the prevalence of Campylobacter-specific an-
tibodies (16–26 %) of healthy BD, about 44–62 % (≈53 %) of
RA cases are associable with Campylobacter. Moreover, tests
to determine H. pylori-, M. pneumoniae-, Y. enterocolitica-,
and B. afzelii-reactive antibodies in all the sera showed higher
Campylobacter-specific antibodies than those of other patho-
gens. The association of yersiniosis and RA is well described
[35, 36] and reconfirmed by the seroprevalence data of this
study. The relatively low B. afzelii seroprevalence rate (8–
20 %) as well as the low rate of double Borrelia and
Campylobacter antibody-positive sera in RA patients (6 %)
indicates that the subgroup of Borrelia-reactive arthritis inter-
feres only to a minor degree with post-Campylobacter RA.
One debatable question is the contribution of
Campylobacter caused episodes of acute gastroenteritis to
the pathogenesis of IBD. Recent investigations in gnotobiotic
mice demonstrated that the composition of the intestinal flora
plays a pivotal role in the pathogenesis of acute
campylobacteriosis. Due to their microbiota composition,
mice display a natural colonization resistance against
C. jejuni [16, 17]. Quantitative analysis of the bacterial gut
flora composition revealed two- to three-fold increased
Escherichia coli loads in intestinal ‘humanized’ mice that are
susceptible to C. jejuni compared to resistant mice recolonized
Table 3 Percentages and absolute numbers of Campylobacter-,
Helicobacter pylori-, Mycoplasma pneumonia-, Yersinia enterocolitica-,
and Borrelia afzelii-positive tested (IgA and IgG) serum samples as well
as percentages and absolute numbers of double positive tested serum













50–57 % (159–183) 9–17 % (28–53) 16–23 % (51–75) 23–35 % (75–112) 13–22 % (42–70)
Helicobacter pylori
IgA+ or IgG+
9–17 % (28–53) 13–23 % (43–73) 4–11 % (13–34) 6–14 % (19–46) 5–11 % (15–35)
Mycoplasma pneumoniae
IgA+ or IgG+
16–23 % (51–75) 4–11 % (13–34) 25–34 % (80–108) 11–21 % (34–68) 6–13 % (18–40)
Yersinia enterocolitica
IgA+ or IgG+
23–35 % (75–112) 6–14 % (19–46) 11–21 % (34–68) 34–50 % (110–159) 11–19 % (35–61)
Borrelia afzelii IgG+ 13–22 % (42–70) 5–11 % (15–35) 6–13 % (18–40) 11–19 % (35–61) 22–29 % (69–94)
Percentages are given in relation to all 320 serum samples included in this study. The absolute numbers of positive until positive plus borderline tested
sera is given in brackets
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with a murine gut flora [16, 17]. Likewise, high-elevated E. coli
amounts increase the susceptibility to S. enterica-caused enter-
itis in mice [37–39]. Here a vicious circle starts because intes-
tinal inflammation is associated with remarkable changes in the
gut microbiota. Intestinal inflammation results in a decrease in
the diversity of natural bacterial species in the gut leading to
overgrowth of commensals such as E. coli, Bacteroides spp.,
and Prevotella spp. [40–44]. This dysbiosis in turn increases
the susceptibility for C. jejuni- and S. enterica-caused enteritis.
Additionally it was shown that E. coli LPS triggers TLR-4-
signalling, which is a key signal for initiation and continuation
of enteritis [41, 42]. Continuous inflammation is one pivotal
parameter in the multifactorial pathogenesis of IBD [13, 45]. In
this regard we are faced with a delicate codependency situation.
On one hand, IBD patients are more susceptible to enteric
pathogens [13, 45, 46], while on the other hand, recurrent
episodes of acute bacterial enterocolitis trigger the manifesta-
tion of IBD in susceptible individuals [11, 12, 47]. Thus, the
significantly (p<0.001) increased Campylobacter-seropreva-
lence in IBD patients, which ranges from 23 to 40 %
(≈32 %), subtracting the prevalence of Campylobacter-specific
antibodies in 16–26% of healthy individuals (BD) in our study,
supports the theory of campylobacteriosis-triggerd IBD as well
as the theory of an increased susceptibility for Campylobacter
in IBD patients. Recent studies performed on rodent mice have
revealed that H. hepaticus and H. bilis employ the same mech-
anism to trigger IBD [48]. Therefore, further studies are re-
quired to determine if a similar situation applies to other enteric
pathogens.
The overall low H. pylori-seroprevalence rate (13–23 %)
and especially the low rate of double Helicobacter- and
Campylobacter-reactive sera (9–17 %) indicates that there is
very little influence of cross-reactivity between both bacterial
species in this study. The reasonably high rate of Yersinia-
antibody positive sera especially among patients who were
also tested Campylobacter-seropositive may be explained by
unspecific (re-) activation of the specific intestinal immune
response against an intestinal pathogen (especially in IBD) but
also by antigenic interference, that would be a significant
weakness in Campylobacter serodiagnostics. Therefore, this
aspect has to be further addressed in future studies.
In conclusion, we show that antigens OMP18+P39 (for IgA)
and P39 (for IgG) have larger ROC AUCs thanWCL, OMP18,
MOMP, PEB1, PEB2 and PEB4 antigens. Therefore, their usage
in diagnostics of previous Campylobacter infections will pro-
duce much more reliable results. In addition, we present valid
data showing that a higher proportion of post-infectious sequel-
ae, namely, GBS, RA and IBD are triggered by Campylobacter
spp. as compared toH. pylori,M. pneumoniae, Y. enterocolitica,
and Borellia spp. However, there is evidence for codependency
between Campylobacter infections and infections with these
pathogens to trigger particular post infectious sequelae.
Therefore, further studies should address how the sum of
antibodies specific for these pathogens increases the risk to
trigger a particular post infectious sequel and to which extent
cross-reactivity of these antibodies affects the specificity of
diagnostic tests.
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